

AMENDMENT TO THE CLAIMS

1. - 32. (Canceled)

33. (Currently Amended) An N-[(piperazinyl)hetaryl]arylsulfonamide compound wherein the compound is N-[6-(4-allylpiperazin-1-yl)pyridin-3-yl]-4-isopropylbenzenesulfonamide, or a physiologically tolerated acid addition salt or N-oxide thereof.

34. (Currently Amended) A pharmaceutical composition which comprises ~~at least one~~ the compound as claimed in claim 33, the ~~and/or at least one~~ physiologically tolerated acid addition salt thereof, or the -of-1 and/or an N-oxide thereof, of 1 together with and a physiologically acceptable ~~carriers~~ carrier and/or ~~an auxiliary substances~~ auxiliary substance.

35. (Currently Amended) A method for treating ~~a medical disorder susceptible to treatment with a dopamine D3 receptor antagonist or a dopamine D3 agonist, the medical disorder selected from the group consisting of~~ a cognitive disturbance, depression, anxiety, addiction, an eating disturbance, a kidney function disturbance, Parkinson's disease and schizophrenia, said method comprising administering an effective amount of the compound of ~~claim 30~~ claim 33 to a subject in need thereof.